Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(5):425–430. doi: 10.1111/j.1349-7006.2003.tb01459.x

Expression of liver‐intestine cadherin and its possible interaction with galectin‐3 in ductal adenocarcinoma of the pancreas

Masaaki Takamura 1,2, Michlle Sakamoto 1,3, Yoshinori Ino 1, Takeshi Shimamura 1, Takafumi Ichida 2, Hitoshi Asakura 2, Setsuo Hirohashi 1,✉
PMCID: PMC11160223  PMID: 12824888

Abstract

Liver‐intestine (LI) cadherin represents a novel type of cadherin within the cadherin superfamily, and is distinguished from other cadherins by specific structural and functional features. Among normal tissues, LI‐cadherin is known to be expressed in the intestinal mucosa, while its expression in cancerous tissue has not been investigated to date, except in gastric carcinoma. In the present study we investigated LI‐cadherin expression immunohis‐tochemically using our newly established monoclonal antibody in a large set (n=102) of tumor specimens from patients with ductal adenocarcinoma of the pancreas, and correlated the findings with the patients' survival. LI‐cadherin expression was seen focally in normal pancreatic ducts. In carcinoma, well‐differentiated carcinoma cases strongly expressed LI‐cadherin, whereas less differentiated areas and poorly differentiated carcinoma cases expressed less or were negative. Kaplan‐Meier analysis for all patients demonstrated that high Ll‐cadherin expression (>25% of cells stained positive) correlated with good survival (P<0.001). Cox regression analyses demonstrated that LI‐cadherin expression was one of the strongest predictors of outcome, independent of all other variables, and low Ll‐cadherin expression correlated with tumor de‐differentiation and advanced stage. Furthermore, galectin‐3 was identified as being coimmunoprecipitated with Ll‐cadherin and this interaction was inhibited by lactose in a dose‐dependent manner, but not by sucrose. Because galectin‐3 has been observed to show a similar expression pattern to LI‐cadherin in ductal adenocarcinoma of the pancreas, expression of LI‐cadherin and this interaction could have some role in ductal adenocarcinoma of the pancreas. (Cancer Sci 2003; 94: 425–430)

References

  • 1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47. [DOI] [PubMed] [Google Scholar]
  • 2. Statistics and Information Department, Minister's Secretariat . Vital statistics of Japan. Tokyo : Ministry of Health, Labour and Welfare; 1999. p. 284–99. [Google Scholar]
  • 3. Conlon KC, Klimstra DS, Brennan MF. Long‐term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5‐year survivors. Ann Surg 1996; 223: 273–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165: 68–72. [DOI] [PubMed] [Google Scholar]
  • 5. Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman J, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Roder JD, Ott K. Cancer of the pancreas. In: Gospodarowicz MK, Henson DE, Hutter RVP, O'Sullivan B, Sobin LH, Wittekind Ch, editors. Prognostic factors in cancer. 2nd ed. New York : Wiley‐Liss; 2001. p. 333–47. [Google Scholar]
  • 7. Ranscht B. Cadherins and catenins: interactions and functions in embryonic development. Curr Opin Cell Biol 1994; 6: 740–6. [DOI] [PubMed] [Google Scholar]
  • 8. Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol 1995; 7: 619–27. [DOI] [PubMed] [Google Scholar]
  • 9. Takeichi M. Cadherins: a molecular family important in selective cell‐cell adhesion. Annu Rev Biochem 1990; 59: 237–52. [DOI] [PubMed] [Google Scholar]
  • 10. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806–11. [DOI] [PubMed] [Google Scholar]
  • 11. Hirohashi S. Inactivation of the E‐cadherin‐mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Berndorff D, Gessner R, Kreft B, Schnoy N, Lajous‐Petter AM, Loch N, Reutter W, Hortsch M, Tauber R. Liver‐intestine cadherin: molecular cloning and characterization of a novel Ca(2+)‐dependent cell adhesion molecule expressed in liver and intestine. J Cell Biol 1994; 125: 1353–69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Dantzig AH, Hoskins JA, Tabas LB, Bright S, Shepard RL, Jenkins IL, Duckworth DC, Sportsman JR, Mackensen D, Rosteck PR Jr, Skatrud PL. Association of intestinal peptide transport with a protein related to the cadherin superfamily. Science 1994; 264: 430–3. [DOI] [PubMed] [Google Scholar]
  • 14. Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver‐intestine cadherin. Ann NY Acad Sci 2000; 915: 136–43. [DOI] [PubMed] [Google Scholar]
  • 15. Grotzinger C, Kneifel J, Patschan D, Schnoy N, Anagnostopoulos I, Faiss S, Tauber R, Wiedenmann B, Geβner R. Ll‐cadherin: a marker of gastric metaplasia and neoplasia. Gut 2001; 49: 73–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Nagafuchi A, Takeichi M. Cell binding function of E‐cadherin is regulated by the cytoplasmic domain. EMBO J 1988; 7: 3679–84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Kreft B, Berndorff D, Bottinger A, Finnemann S, Wedlich D, Hortsch M, Tauber R, Geβner R. LI‐cadherin‐mediated cell‐cell adhesion does not require cytoplasmic interactions. J Cell Biol 1997; 136: 1109–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Watanabe M, Hirohashi S, Shimosato Y, Ino Y, Yamada T, Teshima S, Sekine T, Abe O. Carbohydrate antigen defined by a monoclonal antibody raised against a gastric cancer xenograft. Jpn J Cancer Res 1985; 76: 43–52. [PubMed] [Google Scholar]
  • 19. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H. Clinicopathological significance of galectin‐3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002; 8: 2570–5. [PubMed] [Google Scholar]
  • 20. Sobin LH, Wittekind Ch. TNM classification of malignant tumours. 5th ed. New York : Wiley‐Liss; 1997. [Google Scholar]
  • 21. Japan Pancreas Society . Classification of pancreatic cancer. Tokyo : Kanehara Shuppan Co., Ltd.; 1996. [Google Scholar]
  • 22. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Buchler MW. Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 2001; 49: 539–49. [DOI] [PubMed] [Google Scholar]
  • 23. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, Kloppel G, Lemoine NR. Loss of membranous E‐cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174: 243–8. [DOI] [PubMed] [Google Scholar]
  • 24. Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K, Scarpa A, Fukao K. Pancreatic carcinoma: correlation between E‐cadherin and al‐pha‐catenin expression status and liver metastasis. Cancer 1998; 82: 1649–56. [PubMed] [Google Scholar]
  • 25. Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994; 269: 20807–10. [PubMed] [Google Scholar]
  • 26. Barondes SH, Castronovo V, Cooper DNW, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes RC, Kasai K, Poirier F, Raz A, Rigby P, Rini JM, Wang JL. Galectins: a family of animal beta‐galactoside‐binding lectins. Cell 1994; 76: 597–8. [DOI] [PubMed] [Google Scholar]
  • 27. Kasai K, Hirabayashi J. Galectins: a family of animal lectins that decipher glycocodes. J Biochem (Tokyo) 1996; 119: 1–8. [DOI] [PubMed] [Google Scholar]
  • 28. Ochieng J, Leite‐Browning ML, Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin‐3. Biochem Biophys Res Commun 1998; 246: 788–91. [DOI] [PubMed] [Google Scholar]
  • 29. Ohannesian DW, Lotan D, Thomas P, Jessup JM, Fukuda M, Gabius HJ, Lotan R. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin‐3 in human colon carcinoma cells. Cancer Res 1995; 55: 2191–9. [PubMed] [Google Scholar]
  • 30. Matarrese P, Fusco O, Tinari N, Natoli C, Liu FT, Semeraro ML, Malorni W, Lacobelli S. Galectin‐3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer 2000; 85: 545–54. [PubMed] [Google Scholar]
  • 31. Kim HR, Lin HM, Biliran H, Raz A. Cell cycle arrest and inhibition of anoikis by galectin‐3 in human breast epithelial cells. Cancer Res 1999; 59: 4148–54. [PubMed] [Google Scholar]
  • 32. Inohara H, Raz A. Functional evidence that cell surface galectin‐3 mediates homotypic cell adhesion. Cancer Res 1995; 55: 3267–71. [PubMed] [Google Scholar]
  • 33. Akahani S, Nangia‐Makker P, Inohara H, Kim HR, Raz A. Galectin‐3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl‐2 family. Cancer Res 1997; 57: 5272–6. [PubMed] [Google Scholar]
  • 34. Nangia‐Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A. Galectin‐3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000; 156: 899–909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Song YK, Billiar TR, Lee YJ. Role of galectin‐3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 2002; 160:1069–75. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES